Do you want to read an article? Please log in or register.
BDP/FF/GB single-inhaler triple therapy in COPD: real-world effectiveness, safety, and adherence in a pooled analysis of 5,000 patients
COPD
Related content
RECOMMENDED
COPD
Real-World Efficacy of BDP/FF/G Fixed Triple Inhalation Powder (NEXThaler) Therapy in the Treatment of Moderate to Severe COPD patients (RESPONSE Study)
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Dulai V, Keglevich A, Sánta B, Abonyi-Tóth Z, Horváth I
doi: 10.1016/j.rmed.2025.108498
Asthma
Real-World Safety and Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma: Final Analysis of a Post-Marketing Surveillance in Japan
Adv Ther
Asai K, Morioka Y, Ito R, Komatsubara M, Maruoka H
doi: 10.1007/s12325-025-03421-2
Asthma
Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Initiation in Japanese Patients with Asthma Previously on Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: A Retrospective Cohort Study
J Clin Med
Oga T, Gon Y, Takano M, Ito R, Mita C, Mukai I, Noorduyn SG, Requena G, Yarita M
doi: 10.3390/jcm14082566
COPD
Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan
J Clin Med
Akiyama S, Oda K, Mizohata H, Sasakura N, Hashimoto K, Maruoka H
doi: 10.3390/jcm14134697
COPD
Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β(2)-agonist: post-hoc analyses of KRONOS
Respir Res
Singh D, Bafadhel M, Arya N, Marshall J, Parikh H, Kisielewicz D, Movitz C, Bowen K, Patel M
doi: 10.1186/s12931-025-03234-5
RECOMMENDED
COPDPneumonia
Comparing Major COPD Triple Therapy Trials Using a Structured Multi-Criteria Decision Analysis: A Deep Dive into Patient Populations and Outcomes
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Med
Cazzola M, Maniscalco M, Patella V, Calzetta L, Matera MG, Rogliani P
doi: 10.1016/j.rmed.2025.108292
RECOMMENDED
COPD
TETRIS - Prospective study to observe clinical outcomes of triple therapy in COPD patients: up to 12 months interim analysis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Rohde G, Vogelmeier CF, Beeh KM, Kardos P, Paulsson T, Watz H, Westermayer B, Mohan T, Noorduyn SG, Claussen J
doi: 10.1016/j.rmed.2025.108597
Pulmonary Fibrosis
Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes
Respir Med
Salvatore D, Iacotucci P, Pepe A, Terminiello A, Majo F, Carnovale V, Vitullo P, Messore B, Parisi GF, Calderazzo MA, Leonetti G, Terlizzi V
doi: 10.1016/j.rmed.2025.108221
COPD
Clinical Stability under FF/UMEC/VI Triple Inhaled Therapy: A 12-Month Real Life Retrospective Observational Study
Respir Med
Maniscalco M, Candia C, Pennisi F, Pennisi A, De Simone G, Ambrosino P
doi: 10.1016/j.rmed.2026.108633